Aurobindo Pharma Share Price Fell 5% Amid Zentiva Deal Reports; Company Issues Clarification

On August 20, 2025, Aurobindo Pharma share price (NSE: AUROPHARMA) slipped nearly 5% to ₹1,039 after reports suggested the company was close to acquiring Prague-based drugmaker Zentiva for $5–5.5 billion (₹43,500–47,900 crore).

If finalised, this would be the largest acquisition ever by an Indian pharma company, boosting Aurobindo’s presence in Europe, especially in Eastern markets like the Czech Republic, Romania, and Slovakia.

Company Clarification

Aurobindo issued a regulatory statement under SEBI rules, saying it regularly explores acquisitions and partnerships but has not signed any binding agreement. The company called the news “premature” and assured that any official deal would be disclosed to exchanges as per regulations.

Aurobindo Pharma Financial Performance (Q1 FY26)

• Net profit: ₹824 crore (↓10.2% YoY)
• Revenue: ₹7,868 crore (↑4% YoY)
• EBITDA: ₹1,603 crore vs. ₹1,619.6 crore (slight dip)
• EBITDA margin: 20.4% vs. 21.4% last year

Regional Performance

• US revenue: ₹3,488 crore (↓1.9% YoY) – impacted by destocking and seasonal weakness
• Europe revenue: ₹2,338 crore (↑18% YoY) – strong growth despite overall cautious outlook

Also Read: HAL Share Price in Focus: Government Approves ₹62,000 Crore Deal!

Market Trend

The stock hit a day’s low of ₹1,039.30, down 4.7%. Over the last 12 months, Aurobindo Pharma’s shares have dropped 28%, with a 22% fall year-to-date in 2025, showing investor concerns.

Conclusion

While reports of a record-breaking Zentiva acquisition shook investor sentiment, Aurobindo has clarified that no decision has been made yet. With falling profits but rising European revenue, the company’s next moves, especially on acquisitions will be closely watched by the market.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in securities market are subject to market risks, read all the related documents carefully before investing.